NeuroVive Pharmaceutical AB (STO:NVP) stock shares were registered with
the OTC Reporting Facility for Foreign shares in New York City with the
ticker symbol NEVPF:US on March 20, 2014. NeuroVive trades on the NASDAQ
OMX Stockholm (Sweden) Small Cap since April 2013 with ticker symbol
NVP.ST. The NEVPF shares have been trading in the United States between
$4.00 and $4.21, reflecting the Swedish market value.
NeuroVive Pharmaceutical AB's inclusion in the Grey Market OTC trading
means the share now trades electronically on the US market through
domestic American full-service and internet brokerages houses. The NEVPF
ticker symbol registration was placed by an American retail brokerage
This extends the NeuroVive stock trading day from the Nordic countries
to North America, and by five and half hours until US market closing at
5 p.m. EST (11 p.m. Swedish or Central European Time). OTC trading makes
it straightforward for US investors to easily and electronically invest
in NeuroVive using US currency, with no need to go through a Swedish
brokerage nor convert Swedish krona (SEK). NEVPF share price can be
followed at www.OTCmarkets.com,
or through any American brokerage house.
This early registration of NeuroVive on the American market occurred
because over 4 million NeuroVive shares, or over 15% of all NeuroVive
shares are already in American brokerage houses. The majority of NEVPF
shares are held at E*Trade Securities LLC by Maas Biolab, LLC, the
American company that is the largest shareholder of NeuroVive.
Individuals also hold NEVPF shares in other American brokerages and
branches including Charles Schwab, Fidelity, Janney Montgomery Scott,
Morgan Stanley and UBS.
OTC Markets Group's Open, Transparent and Connected financial
marketplaces provide investors with the information necessary to
intelligently analyze, value and trade 10,000 U.S. and global securities
through the broker of their choice.
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine
company, is developing a portfolio of products to treat acute
cardiovascular and neurological conditions through mitochondrial
protection. These medical conditions are characterized by a pressing
medical need and have no approved pharmaceutical treatment options at
present. NeuroVive's products CicloMulsion® (heart attack) and
NeuroSTAT® (traumatic brain injury) are currently being evaluated in
phase III and phase II studies, respectively. NeuroVive's research
programs also include products for the treatment of anti-viral
indications (Hepatitis B/C), brain cell injury in stroke patients, and
drug candidates for cellular protection and treating
mitochondria-related energy regulation diseases. NeuroVive's shares are
listed on NASDAQ OMX, Stockholm, Sweden.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: + 46 (0)46 888 83 48, www.neurovive.com
NeuroVive Pharmaceutical AB (publ) is required to publish the
information in this news release under The Swedish Securities Market
Act. The information was submitted for publication on 10 April 2014, at
8:30 a.m. CET.
This information was brought to you by Cision http://news.cision.com
[ Back To NFVZone's Homepage ]